Minerva Neurosciences (NERV) Retained Earnings (2013 - 2026)
Minerva Neurosciences (NERV) posted Retained Earnings of -$814.2 million for Q1 2026, down 18.21% on a QoQ basis from -$688.8 million in Q4 2025, and down 103.99% year-over-year from $20.4 billion in Q1 2025.
Minerva Neurosciences (NERV) Retained Earnings (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Retained Earnings history runs 14 years deep, the most recent figure standing at -$814.2 million for Q1 2026.
- Quarterly Retained Earnings fell 103.99% year-over-year to -$814.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$814.2 million (down 103.99% YoY) and the FY2025 annual result came in at -$688.8 million, down 74.21% from the prior year.
- Retained Earnings was -$814.2 million for Q1 2026 at Minerva Neurosciences, down from -$688.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$344.5 million in Q1 2022 and bottomed at -$814.2 million in Q1 2026.
- A 5-year average of -$428.1 million and a median of -$395.4 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings gained 2.71% — and 2026, when it sank 103.99%.
- Minerva Neurosciences' Retained Earnings stood at -$366.8 million in 2022, then decreased by 8.18% to -$396.8 million in 2023, then gained by 0.36% to -$395.4 million in 2024, then slumped by 74.21% to -$688.8 million in 2025, then fell by 18.21% to -$814.2 million in 2026.
- Business Quant data shows NERV's Retained Earnings at -$814.2 million in Q1 2026, -$688.8 million in Q4 2025, and -$405.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -814.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -814.20 Mn |
| Dec 31, 2025 | -688.80 Mn |
| Sep 30, 2025 | -405.10 Mn |
| Jun 30, 2025 | -402.39 Mn |
| Mar 31, 2025 | -399.13 Mn |
| Dec 31, 2024 | -395.38 Mn |
| Sep 30, 2024 | -391.10 Mn |
| Jun 30, 2024 | -413.62 Mn |
| Mar 31, 2024 | -405.40 Mn |
| Dec 31, 2023 | -396.82 Mn |
| Sep 30, 2023 | -387.80 Mn |
| Jun 30, 2023 | -379.97 Mn |
| Mar 31, 2023 | -373.80 Mn |
| Dec 31, 2022 | -366.81 Mn |
| Sep 30, 2022 | -360.10 Mn |
| Jun 30, 2022 | -353.20 Mn |
| Mar 31, 2022 | -344.47 Mn |
| Dec 31, 2021 | -334.70 Mn |
| Sep 30, 2021 | -313.39 Mn |
| Jun 30, 2021 | -304.19 Mn |